ISCO Has Developed Human Stem Cell Lines That Could Potentially
Eliminate Problems of Immune Rejection
International Stem Cell Corporation (OTCBB: ISCO)
announced today that the Data Trends Equity Research Group, a unit of
DataTrends Publications, Inc., publisher of Stem Cell Business News and
the Guide to Stem Cell Research Companies, has released its
Investor's Corporate Profile® of International
Stem Cell Corporation.
This timely, comprehensive report, published in PDF format, is available
at http://www.stemcellresearchnews.com/DERG_Page.htm.
International Stem Cell Corporation (ISCO.OB) has developed breakthrough
human stem cell lines that they believe have the potential to eliminate
the rejection of transplanted cells by the patient's immune system.
ISCO's technology, parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs without
the transfer of foreign DNA. This methodology offers the potential to
create the first true "stem cell bank" and also addresses critical
ethical issues by eliminating the need to use fertilized embryos. ISCO
also produces and sells specialized cells and growth media worldwide for
therapeutic research through its Maryland-based subsidiary, Lifeline
Cell Technology. ISCO's goal is to be the world leader in providing
human cells to study and cure disease.
The Company plans to manufacture clinical and research products for the
treatment of diabetes, liver disease, and retinal disease. In addition,
ISCO is open to acquiring, partnering or forming joint ventures with
companies that will be synergistic to its strategic endeavors. The
Company is focused on human diseases that have already been shown in
clinical tests to respond positively to cell transplantation (the use of
functional human cells to replace cells that have been lost or damaged
due to disease). ISCO has derived therapeutic cells from human
parthenogenic stem cells (hpSCs) using technologies that promise to
solve two critical problems with current cell transplantation
methodologies: immune rejection, and a lack of sufficient cells to treat
patients in need. The cells in development will not be derived from
fertilized human embryos.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
For more news and information on International Stem Cell Corporation
please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more.
About International Stem Cell Corporation (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of pluripotent
human stem cell lines from unfertilized human eggs. ISCO scientists have
created the first Parthenogenetic homozygous stem cell line
(phSC-Hhom-4) that can be a source of therapeutic cells that will
minimize immune rejection after transplantation into hundreds of
millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
About DataTrends Publications, Inc., and DataTrends Equity Research
Group
DataTrends Publications, Inc., founded in 1987, is the publisher of Stem
Cell Research News (founded 1999), Stem Cell Business News
(2002), and Stem Cell Lab World (2007), as well as semi-annual Guide
to Stem Cell Research Companies. DataTrends Equity Research Group, a
unit of DataTrends Publications, provides independent research to small,
growth-oriented public companies. DERG's Investor's Corporate Profile®
is a comprehensive, detailed summary of a company's business and growth
strategies, history, financial data, leadership, science & technology,
commercial products and products in the pipeline, markets, competition,
patent portfolio and other intellectual property, strategic alliances,
and risk factors. The Profile does not forecast the market or provide
target stock prices, and does not recommend buys, sells, or holds.
DataTrends Publications, Inc., was not compensated by International Stem
Cell Corporation, except for incidental printing, production, and other
costs, if any, for the development of this Profile.
Forward-Looking Safe Harbor Statement
Statements pertaining to anticipated future financial and/or operating
results, future growth in research, technology, clinical development and
potential joint venture and other opportunities for International Stem
Cell Corporation and its subsidiary, along with other statements about
the future expectations, beliefs, goals, plans, or prospects expressed
by management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the Company's business, particularly those
mentioned in the cautionary statements found in the Company's Securities
and Exchange Commission filings.
These statements, and other forward-looking statements, are not
guarantees of future performance. Both DataTrends Publications, Inc.,
and the Company disclaim any intent or obligation to update these
forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO kaldrich@intlstemcell.com 760-940-6383 or Jeffrey
Janus, President jjanus@intlstemcell.com 760-940-6383 or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |